vTv Therapeutics Inc. 8-K

What Happened
vTv Therapeutics Inc. (through its subsidiary vTv Therapeutics LLC) filed an 8-K (Item 1.01) reporting that on January 30, 2026 it entered into a Second Amendment to its May 31, 2018 license agreement with Newsoara Biopharma Co., Ltd. The amendment expands Newsoara’s rights in vTv’s PDE4 inhibitor HPP737 to include all countries worldwide upon Newsoara’s payment of a $20 million upfront fee. A prior amendment that had expanded the agreement became null and void in June 2025. The company said it will file the Second Amendment as an exhibit to its Form 10-K for the year ended December 31, 2025.

Key Details

• Parties: vTv Therapeutics LLC (subsidiary of vTv Therapeutics Inc.) and Newsoara Biopharma Co., Ltd.
• Date signed: January 30, 2026; original license dated May 31, 2018; prior amendment voided June 2025.
• Cash and milestones: $20 million upfront; up to $50 million in development milestones; up to $65 million in sales-related milestones.
• Royalties: mid-single-digit royalties on sales (rate dependent on sales volumes).

Why It Matters
The deal provides vTv with immediate cash ($20M) and potential future payments (up to $115M in milestones plus royalties) tied to HPP737’s development and commercial success. For investors, this shifts global commercialization rights for HPP737 to Newsoara while creating a clear, milestone‑based revenue pathway for vTv rather than direct commercialization. Watch for the filed Second Amendment in vTv’s 2025 Form 10-K and future disclosures about timing of payments, development progress, and any impact on vTv’s financials or liquidity.